Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vered Stearns

Showing results (111-120 of 273) with videos related to

Pageof 28
Sort By:
JCO Oncology Practice|February 17, 2021
Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot StudyMirat Shah, Anna Ferguson, Phyllis Dvora Corn, et al.
Journal of the National Cancer Institute|December 5, 2003
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineVered Stearns, Michael D Johnson, James M Rae, et al.
Journal of Cancer Survivorship : Research and Practice|June 1, 2023
Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancerAnna-Carson Rimer Uhelski, Amanda L Blackford, Jennifer Y Sheng, et al.
Carcinogenesis|May 3, 2019
Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical studyGuannan Wang, Chuang Chen, Priya Pai, et al.
Frontiers in Pharmacology|April 6, 2012
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genesSantosh Philips, James M Rae, Steffi Oesterreich, et al.
Cancer|June 16, 2010
A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonographyN Lynn Henry, Jon A Jacobson, Mousumi Banerjee, et al.
Frontiers in Bioengineering and Biotechnology|March 12, 2020
Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint InhibitorsHanwen Wang, Richard J Sové, Mohammad Jafarnejad, et al.
Biomedicines|November 25, 2023
Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic ConditionsNada Lukkahatai, Jongmin Park, Hejingzi Monica Jia, et al.
Molecular & Cellular Proteomics : MCP|September 3, 2015
Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast CancerXinyan Wu, Muhammad Saddiq Zahari, Santosh Renuse, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJames M Rae, Suzy Drury, Daniel F Hayes, et al.
Pageof 28

Showing results (111-120 of 273) with videos related to

Sort By:
Pageof 28
JCO Oncology Practice|February 17, 2021
Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot StudyMirat Shah, Anna Ferguson, Phyllis Dvora Corn, et al.
Journal of the National Cancer Institute|December 5, 2003
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineVered Stearns, Michael D Johnson, James M Rae, et al.
Journal of Cancer Survivorship : Research and Practice|June 1, 2023
Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancerAnna-Carson Rimer Uhelski, Amanda L Blackford, Jennifer Y Sheng, et al.
Carcinogenesis|May 3, 2019
Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical studyGuannan Wang, Chuang Chen, Priya Pai, et al.
Frontiers in Pharmacology|April 6, 2012
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genesSantosh Philips, James M Rae, Steffi Oesterreich, et al.
Cancer|June 16, 2010
A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonographyN Lynn Henry, Jon A Jacobson, Mousumi Banerjee, et al.
Frontiers in Bioengineering and Biotechnology|March 12, 2020
Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint InhibitorsHanwen Wang, Richard J Sové, Mohammad Jafarnejad, et al.
Biomedicines|November 25, 2023
Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic ConditionsNada Lukkahatai, Jongmin Park, Hejingzi Monica Jia, et al.
Molecular & Cellular Proteomics : MCP|September 3, 2015
Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast CancerXinyan Wu, Muhammad Saddiq Zahari, Santosh Renuse, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJames M Rae, Suzy Drury, Daniel F Hayes, et al.
Pageof 28